Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post-liver transplant recipients [1]

Liver Transplantation

Volumn 12, Issue 6, 2006, Pages 1020-1021

  Jain, Ashok ^a   Mohanka, Ravi ^a   Orloff, Mark ^a   Abt, Peter ^a   Ryan, Charlotte ^a   Bozorgzadeh, Adel ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTERASE; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; ENTEROPATHY; HUMAN; INFECTION PREVENTION; LETTER; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PUBLICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 33745483640     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20749     Document Type: Letter

References (7)

1. Park JM, Lake KD, Arenas JD, Fontana RL Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2005;12:112-116.
2. Pescovitz MD. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transpi Infect Dis 1999;1(Suppl):31-34.
3. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811-2815.
4. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002;72:142-150.
5. Jain AB, Orloff M, Lansing K, Kashyap, R, Kelley M, Betts R, et al. Valgan (ganciclovir hydrochloride) provides ineffective prophylaxis against cytomegaloviral (CMV) infection in liver transplant recipients [abstract]. Am J Transplant 2004;4(Suppl 8):569.
6. Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005;37: 3182-3186.
7. Valcyte (valganciclovir hydrochloride tablets) complete product information. Available at: http://www.roche-usa.com/products/valcyte/ pi.pdf. Accessed January 4, 2006.